'Advances in Clinical Flow Cytometry' roadshow by BD provides rich knowledge-sharing platform to clinicians

May 20, 2022 23:30 IST | ANI Press Release
Tennis player James Blake
Advances in Clinical Flow Cytometry Tour (ACFC) May 2022

New Delhi [India], May 20 (ANI/NewsVoir): To enable knowledge-sharing of best practices and technological advancement on clinical applications of flow cytometry, BD Life Sciences-Biosciences, a segment of BD (Becton, Dickinson and Company) recently organized the 'Advances in Clinical Flow Cytometry' (ACFC) multi-city roadshow for clinicians and physicians.

Organized in Bengaluru, Dhaka, Lucknow and Mumbai, each of the ACFC events also enabled discussions by experts from the clinical fraternity on critical aspects of clinical diagnostics including: Standardization, Performance, Accreditation, Automation and Collaboration.

Commenting on the ACFC initiative, Pavan Mocherla, Managing Director, BD India/South Asia said, "Over the years, flow cytometry has proven to be an invaluable asset in several clinical applications and plays an important role in clinical diagnostics and research. Cognizant of this and aligned with our purpose of Advancing the World of Health, BD has been organizing the Advances in Clinical Flow Cytometry (ACFC) knowledge sharing sessions for clinicians and hematologists across the country since 2018. Our objective is to provide a platform to discuss new processes, and leading technology best practices to enable better patient outcomes and I am happy to share that we engage with more than 150 leading clinicians and medical professionals annually under this platform."

At this edition of ACFC, several clinical applications and importance of quality were discussed by eminent speakers from the clinical fraternity. Key highlights of the discussions were:

- Case studies on Leukemia and Lymphoma as well as Minimal Residual Disease amongst others.

- Deliberation on standard operating protocols, accuracy and standardization of flow cytometry assays.

- Importance of Quality and standardization of assays in clinical flow cytometry.

Commending the ACFC initiative, Dr Arun Kumar Arunachalam - MD, PDF, Assistant Professor, Department of Hematology Christian Medical College, Vellore, said, "Advances in clinical flow cytometry is a wonderful initiative by BD towards bringing together the people who are involved in clinical flow cytometry in the country. The event provided a wonderful platform for discussion and interaction among the participants on various topics that are important and relevant in today's era."

Present at the event, Dr Ananthvikas Jayaram - Pathologist, Neuberg Anand Reference Laboratory, Bengaluru said, "The ACFC meet organized by BD brought pathologists who practice flow cytometry together in-person after the last two years of virtual meetings. The lengthy discussions on assay parameters, troubleshooting, utility of different markers and the debate on standardization were all testament to the quality of the program and the interest it generated among attendees. We look forward to many more such meetings in the future."

Flow Cytometry is a process used to sort, separate and examine microscopic particles, such as cells and chromosomes. It plays an important role in clinical diagnostics and research.

BD offers a growing portfolio of flow cytometry instruments for Leukemia/Lymphoma phenotyping, stem cell research, immunology, and CD4 testing.

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care.

BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to health care.

This story is provided by NewsVoir. ANI will not be responsible in any way for the content of this article. (ANI/NewsVoir)


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)


Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor